Avamys Product Overview
Avamys (fluticasone furoate) is indicated for the treatment of symptoms of allergic rhinitis in adults, adolescents and children (aged two and over). 1
*Vs fluticasone propionate, budesonide, mometasone furoate and ciclesonide.
**Multicentre, randomised, double-blind, crossover study (n=300) where patient preferences were determined by using three questionnaires (Overall Preference, Immediate Attributes and Delayed Attributes).
AR: allergic rhinitis; FFNS: fluticasone furoate nasal spray; INCS: intranasal corticosteroids; MFNS: mometasone furoate nasal spray
References
- Fluticasone Furoate Global Data Sheet; version 11, 03 April 2018.
- Canonica GW, Mullol J, Pradalier A, Didier A. Patient perceptions of allergic rhinitis and quality of life: findings from a survey conducted in Europe and the United States. World Allergy Organ J 2008;1(9):138–144.
- Seidman M, Gurgel RK, Lin SY, et al. Clinical Practice Guideline: Allergic Rhinitis.Otolaryngol Head Neck Surg 2015;152(18):S1–S43.
- Linneberg A, Dam Petersen K, Hahn-Pedersen J, et al. Burden of allergic respiratory disease: a systematic review. Clin Mol Allergy 2016;14:12.
- Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl. 86):8–160.
- Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc. 2008;29(3);313–321.
- Baumann D, Bachert C, Högger P. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. Clin Exp Allergy. 2009;39(10):1540–1550.
- Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8(1):54.
- Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:L660–667.
- Yanez A, Dimitroff A, Bremner P, et al. A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis. Allergy Rhinol 2016;7(4):e183–e192.
- Brozek J, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958.
- Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2017;47:856–889.
- Wallace DV, Dykewicz MS, Oppenheimer J, et al. Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance from the 2017 Joint Task Force on Practice Parameters. Ann Intern Med. 2017;167(12):876–881.
- Santos A, Borrego LM, Rotiroti G, et al. The need for patient-focused therapy for children and teenagers with allergic rhinitis: a case-based review of current European practice. Clin Transl Allergy. 2015;5:2.
Avamys is a registered trademark of the GlaxoSmithKline group of companies